Amid uncertainty over how the Trump administration would approach mRNA COVID-19 vaccines for the upcoming respiratory virus season, the FDA has approved updated shots from Pfizer and Moderna. But ...

A messenger RNA combination vaccine that Pfizer and BioNTech are developing for both Covid-19 and influenza posted mixed results in a pivotal study, meeting just one of the two main goals assessing ...

BERLIN - The scientist who won the race to deliver the first widely used coronavirus vaccine says people can rest assured the shots are safe, and the technology behind it will soon be used to fight ...

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced top-line results from their Phase 3 clinical trial to evaluate ...

Pfizer and BioNTech may have a strong pedigree in the mRNA vaccine game, but, when it comes to flu, they’ve run up against the same problem as their peers—neutralizing influenza strain B. The two ...

The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains 1 Shipping of the LP.8.1-adapted vaccine will ...

Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to ...

(Reuters) - Pfizer Inc is considering a collaboration with German drugmaker BioNTech SE to develop vaccines for the coronavirus using BioNTech's mRNA-based drug development platform, Pfizer's R&D head ...

It seeks an overnight block trade of about 4.55 million American depositary receipts, priced between $108 and $111.70 apiece, according to a Bloomberg report. The sale could fetch roughly $508 million ...

Pfizer has axed 11 programs including two pipeline assets from its $43 billion Seagen acquisition, work on a BioNTech-partnered mRNA vaccine and a midstage metabolic dysfunction-associated ...

Pfizer is selling its remaining stake in COVID-19 vaccine partner BioNTech. The U.S. drugmaker is offering about 4.55 million American depositary receipts in an overnight block trade, marketed at ...

The CHMP’s recommendation will be reviewed by the European Commission (EC), which is expected to make its final decision soon. Pfizer and BioNTech have already initiated manufacturing of the ...